Supplement
Effective for Common Depression
Healthnotes Newswire (December 8, 2005)—Chromium
supplements can relieve symptoms in some patients suffering from
one type of depression (atypical depression), reports the Journal
of Psychiatric Practice (2005;11:302–14).
Atypical depression, one of the most common forms
of depression, is characterized by mood reactivity (increased
sensitivity to being rejected by another person and improved mood
when something good happens), increased appetite, excessive sleepiness,
and sluggishness. Compared with other forms of depression, atypical
depression tends to persist longer and is associated with more
thoughts of suicide and greater disability.
Chromium is an essential trace mineral that plays a role in regulating
blood sugar by enhancing the action of insulin. In people with
a common blood-sugar-regulation disorder known as reactive hypoglycemia,
chromium supplementation prevents the excessive decline in blood-sugar
levels and decreases the associated symptoms. Chromium also influences
the sensitivity of certain receptors on brain cells that help
control a person’s mood. In previous studies, chromium supplementation
was beneficial for people suffering from dysthymia, a mood disorder
related to depression.
The symptoms of atypical depression overlap with those associated
with reactive hypoglycemia. If atypical depression is a manifestation
of reactive hypoglycemia in some people, then chromium supplementation
might be helpful for them.
In the new study, 75 people with atypical depression, most of
whom were overweight or obese, received either 600 mcg per day
of chromium (as chromium picolinate) or a placebo for eight weeks.
The proportion of people who improved by at least 50% (responders)
was greater in the chromium group than in the placebo group (54%
versus 36%), although this difference was not statistically significant.
However, significant differences were seen when the analysis was
restricted to those people who reported that they had severe carbohydrate
craving (a possible indicator of abnormal glucose metabolism).
In that subset, the proportion of responders was 65% in the chromium
group and only 33% in the placebo group, a statistically significant
difference. No significant side effects were observed in people
taking chromium.
The results of this study indicate that people with atypical depression
who also crave carbohydrates are likely to improve if they take
600 mcg of chromium per day. If chromium works by improving blood-glucose
regulation, then its effects might be enhanced by dietary changes
(avoiding refined sugar, caffeine, and alcohol, and eating small,
frequent meals) and by supplementing with other blood-glucose-stabilizing
nutrients, including B vitamins, magnesium, zinc, and copper.
Regular aerobic exercise may also relieve depression, possibly
by improving insulin sensitivity and blood-sugar control.